

Ref: FOI/GS/ID 7350

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

14 April 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Metastatic/advanced Breast cancer.

You asked:

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

- a. Abemaciclib (Verzenios) + aromatase inhibitor **
- b. Abemaciclib (Verzenios) + Fulvestrant (Faslodex)*
- c. Alpelisib (Piqray) + Fulvestrant (Faslodex)*
- d. Atezolizumab (Tecentriq)***
- e. Bevacizumab (Avastin)*
- f. Eribulin (Halaven)*
- g. Everolimus (Afinitor) + Exemestane*
- h. Fulvestrant (Faslodex) as a single agent*
- i. Gemcitabine + paclitaxel*
- j. Herceptin (Trastuzumab) + paclitaxel*
- k. Herceptin (Trastuzumab) as a single agent*
- l. Lapatinib (Tyverb)*
- m. Neratinib (Nerlynx)*
- n. Olaparib (Lynparza)*
- o. Palbociclib (Ibrance) + aromatase inhibitor**
- p. Palbociclib (Ibrance) + Fulvestrant (Faslodex)*
- q. Pertuzumab (Perjeta) + trastuzumab + docetaxel*
- r. Ribociclib (Kisqali) + aromatase inhibitor**
- s. Ribociclib (Kisqali) + Fulvestrant (Faslodex)*
- t. Talazoparib (Talzenna)*
- u. Trastuzumab emtansine (Kadcyla)*
- v. Other active systemic anti-cancer therapy ***

**aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole*

***e.g. docetaxel, vinorelbine or capecitabine as a single agent*

Q2. For the above patients, how many of these received their first ever dose for each product line?

Trust response:

Q1.

a. 0

b. 2

c. 0

d. 0

e. 0

f. 0

g. 0

h. 2

i. 0

j. 0

k. 2

l. 0

m. 0

n. 0

o. 5

p. 3

q. 0

r. 2

s. 0

t. 0

u. 0

v. 8

Q2.

4 in total

1 - Palbociclib (Ibrance) + Fulvestrant (Faslodex)

3 - for other